Aehr test systems director Posedel sells $1.21 million in stock

Aehr Test Systems disclosed a director sale of 15,000 shares at $80.72 for $1.21 million, while the stock has surged 891% over the past year and trades near $80.85. Operationally, the company reported Q3 EPS of -$0.05 versus -$0.07 expected and revenue of $10.3 million versus $10.8 million expected, but bookings hit a record $37.2 million and backlog topped $50 million. Aehr also announced a record $41 million production order tied to package-level burn-in for custom AI processor ASICs, and analysts raised price targets to $61 and $56.

Analysis

AEHR is shifting from a single-name momentum story to a demand-validation story, but the market has already priced in a lot of that transition. The key second-order effect is that hyperscale AI burn-in demand can pull forward orders for the entire reliability-test stack: sockets, modules, and thermal handling vendors should see a multi-quarter cycle of elevated utilization before revenue fully converts, which means the near-term read-through is better for suppliers than for the stock if execution slips.

The insider sale matters less as a bearish signal than as a liquidity test at an extreme valuation. After a near-vertical re-rating, the stock is now vulnerable to any mismatch between bookings and billings because the backlog is still concentrated and long-dated; if even one production ramp shifts by a quarter, the multiple can compress faster than consensus expects. The real risk is not demand destruction, but customer concentration and timing risk—this is a classic “great order, fragile model” setup.

Consensus seems to be underestimating how much of the good news is already forward-discounted. A large order and record bookings improve the narrative, but they also raise the bar for gross margin stability, deployment cadence, and follow-on orders; without those, the stock can stagnate despite positive headlines. The contrarian view is that the better trade may be the ecosystem beneficiaries and volatility expression, not outright chasing AEHR at current levels.

Key Decisions for Investors

• Avoid initiating fresh long AEHR common here; if already long, trim 25-50% into strength and keep the rest only if there is confirmed conversion of backlog into revenue over the next 1-2 quarters.
• Sell AEHR call spreads or buy put spreads with 2-4 month tenor to express the view that the stock can de-rate even if fundamentals remain constructive; risk/reward favors defined-risk downside after the run.
• Long basket of adjacent beneficiaries on pullbacks over the next 1-3 months: the AI test/packaging supply chain should capture more durable revenue than AEHR’s lumpy customer wins.
• Pair trade: long a more diversified AI hardware enabler vs short AEHR for 1-2 quarters, betting that execution risk and valuation mean-reversion matter more than headline order flow.
• Set a catalyst watch on the next two reporting dates; if bookings remain strong but revenue does not inflect, use that as the inflection point to press shorts or add hedges.